𝐖𝐞 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚𝐭 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐨𝐧 𝐓𝐚𝐫𝐠𝐞𝐭 𝟐𝟎𝟐𝟔!

This year’s program covers emerging drug targets and modalities across therapeutic areas, right where organelle biology lives. Lysosomal and mitochondrial targets are increasingly central to neurodegeneration, oncology and beyond. We believe meaningful SAR data on these targets starts with access to native, functional organelles.

At ORIA Bioscience, we are pioneers in organelle science. Our patented microfluidic platform isolates entire, functional organelles at scale, with the reproducibility needed to generate reliable data across these targets. Our technology is built to push target validation forward across therapeutic areas.

📍 𝐒𝐞𝐩 𝟐𝟖 𝐭𝐨 𝐎𝐜𝐭 𝟏, 𝐁𝐨𝐬𝐭𝐨𝐧, 𝐌𝐀
✔️ 𝐁𝐨𝐨𝐭𝐡 #𝟒𝟐𝟏
✔️ 𝐏𝐨𝐬𝐭𝐞𝐫 𝐂𝟎𝟔𝟒: 𝘈 𝘔𝘦𝘥𝘪𝘶𝘮-𝘛𝘩𝘳𝘰𝘶𝘨𝘩𝘱𝘶𝘵 𝘖𝘳𝘨𝘢𝘯𝘦𝘭𝘭𝘦-𝘉𝘢𝘴𝘦𝘥 𝘛𝘰𝘰𝘭𝘣𝘰𝘹 𝘵𝘰 𝘐𝘯𝘵𝘦𝘳𝘳𝘰𝘨𝘢𝘵𝘦 𝘋𝘪𝘷𝘦𝘳𝘴𝘦 𝘋𝘳𝘶𝘨 𝘛𝘢𝘳𝘨𝘦𝘵𝘴 𝘈𝘤𝘳𝘰𝘴𝘴 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘈𝘳𝘦𝘢𝘴